Document is current
Any future updates will be listed below
-
Authors
Williams, Teresa C.
Loo, Su-Ling
Nichol, Kristy S.
Reid, Andrew T.
Veerati, Punnam C. https://orcid.org/0000-0003-1612-0907
Esneau, Camille
Wark, Peter A. B. https://orcid.org/0000-0001-5676-6126
Grainge, Christopher L.
Knight, Darryl A.
Vincent, Thomas
Jackson, Crystal L.
Alton, Kirby
Shimkets, Richard A.
Girkin, Jason L. https://orcid.org/0000-0002-0739-1070
Bartlett, Nathan W. https://orcid.org/0000-0002-2715-5163
-
Funding
Funding for this research was provided by:
Abeome Corporation / Lanier Therapeutics
- License Information
-
More Information
Article History
Received: 28 November 2021
Accepted: 13 April 2022
First Online: 4 May 2022
Competing interests
: NWB reports grants, personal fees for consultancy and other (stock options) from Abeome Corporation/Lanier Biotherapeutics during the conduct of the study; has a patent PCT WO2017160587A1. KA is an employee of Abeome Corporation and owns stock/options in Abeome Corporation and Lanier Biotherapeutics. RAS reports personal fees for consultancy and owns stock/options in Abeome Corporation and Lanier Biotherapeutics; has a patent PCT WO2017160587A1. CLJ is an employee of Lanier Biotherapeutics and owns stock/options in Abeome Corporation and Lanier Biotherapeutics; has a patent PCT WO2017160587A1. The remaining authors declare no competing interests.
